MA45623A - Traitement d'une maladie vasculaire rétinienne utilisant des cellules progénitrices - Google Patents

Traitement d'une maladie vasculaire rétinienne utilisant des cellules progénitrices

Info

Publication number
MA45623A
MA45623A MA045623A MA45623A MA45623A MA 45623 A MA45623 A MA 45623A MA 045623 A MA045623 A MA 045623A MA 45623 A MA45623 A MA 45623A MA 45623 A MA45623 A MA 45623A
Authority
MA
Morocco
Prior art keywords
progenitor cells
treatment
retinal vascular
vascular disease
cells
Prior art date
Application number
MA045623A
Other languages
English (en)
Inventor
Nadine Sophia Dejneka
Ian Harris
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA45623A publication Critical patent/MA45623A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des procédés et des compositions pour traiter une maladie ophtalmique, réduire la néovascularisation rétinienne et les fuites vasculaires rétiniennes à l'aide de cellules progénitrices, telles que des cellules dérivées du postpartum, et d'un milieu conditionné provenant des cellules.
MA045623A 2016-07-05 2017-06-28 Traitement d'une maladie vasculaire rétinienne utilisant des cellules progénitrices MA45623A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662358389P 2016-07-05 2016-07-05

Publications (1)

Publication Number Publication Date
MA45623A true MA45623A (fr) 2019-05-15

Family

ID=59363222

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045623A MA45623A (fr) 2016-07-05 2017-06-28 Traitement d'une maladie vasculaire rétinienne utilisant des cellules progénitrices

Country Status (16)

Country Link
US (1) US20180015129A1 (fr)
EP (1) EP3481405A1 (fr)
JP (1) JP2019524688A (fr)
KR (1) KR20190026758A (fr)
CN (1) CN109414460A (fr)
AR (1) AR108972A1 (fr)
AU (1) AU2017291707A1 (fr)
BR (1) BR112019000059A2 (fr)
CA (1) CA3029997A1 (fr)
MA (1) MA45623A (fr)
MX (1) MX2019000050A (fr)
PH (1) PH12018502704A1 (fr)
RU (1) RU2019102933A (fr)
SG (1) SG11201811100RA (fr)
TW (1) TW201811344A (fr)
WO (1) WO2018009385A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114712393B (zh) * 2020-12-18 2024-01-19 中国人民解放军海军军医大学第三附属医院 Hnf-1α基因修饰的间充质干细胞在防治肝癌中的用途
CN115014908A (zh) * 2022-05-23 2022-09-06 江西中医药大学 染色剂、心脏切片制备方法及微血管灌注染色评价方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707643A (en) 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5718922A (en) 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
CA2370330C (fr) 1999-04-16 2009-01-20 Wm. Marsh Rice University Reseaux biodegradables de poly(propylene fumarate) reticule avec des macromeres de poly(propylene fumarate)-diacrylate
US6355699B1 (en) 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
ES2600555T3 (es) 2003-06-27 2017-02-09 DePuy Synthes Products, Inc. Reparación y regeneración de tejido ocular usando células derivadas del post parto
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
PL1979050T3 (pl) * 2005-12-28 2017-09-29 DePuy Synthes Products, Inc. Leczenie chorób naczyń obwodowych z zastosowaniem komórek pochodzenia poporodowego

Also Published As

Publication number Publication date
JP2019524688A (ja) 2019-09-05
BR112019000059A2 (pt) 2019-10-01
AU2017291707A1 (en) 2019-01-03
US20180015129A1 (en) 2018-01-18
PH12018502704A1 (en) 2019-11-11
AR108972A1 (es) 2018-10-17
MX2019000050A (es) 2019-05-02
EP3481405A1 (fr) 2019-05-15
CN109414460A (zh) 2019-03-01
KR20190026758A (ko) 2019-03-13
CA3029997A1 (fr) 2018-01-11
RU2019102933A (ru) 2020-08-05
WO2018009385A1 (fr) 2018-01-11
TW201811344A (zh) 2018-04-01
SG11201811100RA (en) 2019-01-30

Similar Documents

Publication Publication Date Title
MA41013B1 (fr) Compositions comprenant des souches bactériennes
MA40755B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
MA42560B1 (fr) Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
MA40306A1 (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
MA41060B1 (fr) Compositions comprenant des souches bactériennes
MA55434B1 (fr) Compositions comprenant des souches bactériennes
MA40123A1 (fr) Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
MA41010B1 (fr) Compositions comprenant des souches bactériennes
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
EA202090497A1 (ru) Соединения и композиции для лечения гематологических нарушений
MX2019000965A (es) Composiciones y metodos para inihibir la masp-3 para el tratamiento de diferentes enfermedades y trastornos.
MA39219A1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
MY186271A (en) Ophthalmic compositions and methods of use therefor
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
EP4275761A3 (fr) Agents au phosphatase alcaline pour le traitement de troubles dus à une exposition à des radiations
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
MA45623A (fr) Traitement d'une maladie vasculaire rétinienne utilisant des cellules progénitrices
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
MX2022003236A (es) Bencimidazol carboxamidas sustituidas y su uso en el tratamiento de trastornos medicos.
MX2021001393A (es) Composiciones para el tratamiento de la enfermedad de injerto contra huesped.
MA54326B1 (fr) Compositions pour le traitement de la chute des cheveux